MS and Demyelinating Disorders

More than 95% of the cohort of elderly patients showed functional improvement at 6 months after plasma exchange, including 60% who experienced moderate-to-marked improvement.

Anastasia Vishnevetsky, MD, an immunology fellow at Brigham and Women’s Hospital, provided insight on the latest research initiatives in MOG-antibody associated disease, including the potential for the first FDA-approved therapy.

Here's some of what is coming soon to NeurologyLive® this week.

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease (PD).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 31, 2023.

Foralumab, a fully human anti-CD3 monoclonal antibody, has had treatment effect demonstrated in patients with COVID-19 and with multiple sclerosis, as well as in healthy normal individuals.

Michael Levy, MD, PhD, associate professor at Harvard Medical School, talked about the differences between multiple sclerosis and neuromyelitis optica spectrum disorder, the currently available treatments, and next steps in research.

Disease activity, severity, or effect of treatment in patients with NMOSD may be predicted by aminoacyl-tRNA synthetase-interacting multifunctional protein-1.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, comments on the different modes of administration of DMTs in MS, focusing on oral DMTs.

Experts in neurology assess the risk of disease progression in a patient with MS and identify various biomarkers and diagnostic tools used to detect this.

Elaine Kingwell, PhD, senior research associate at University College London provided perspective on a study presented at the 2023 ACTRIMS Forum on HIV and multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 24, 2023.

Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of disease-modifying therapies for the treatment of multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 17, 2023.

The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

The neurologist at Mayo Clinic, in Jacksonville, Florida, spoke about inebilizumab as a treatment for NMOSD and other autoimmune diseases, such as encephalitis, in the ExTINGUISH trial. [WATCH TIME: 3 minutes]

In honor of Brain Awareness Week, held March 13, 2023, to March 19, 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

At the 2023 ACTRIMS forum, Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, talked about investigating the relationship between viral infections and multiple sclerosis using MRIs.

In a recent interview, the associate professor at Harvard Medical School spoke about patient-centered research in the advancing treatment for patients with NMOSD. [WATCH TIME: 5 minutes]

Michael Dwyer, PhD, director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center, provided insight on how artificial intelligence techniques may be used to monitor disease progression in multiple sclerosis.